BRD2 and infection: A limitation of this efficacy study is that the risk estimates are totally dependent on the assumptions for the input parameters of the Weusten models (in particular, the choice of the ID50 in anti-HBc-negative and-positive infection stages) and the reliability of the projected Ultrio Plus ID-NAT and HBsAg screening data.